Verrica Pharmaceuticals (VRCA) Q2 FY26 earnings call

Verrica Pharmaceuticals reported strong commercial momentum for YCAMP in Q2 FY26, with significant growth in both net product revenue and dispensed units. The company also secured a non-dilutive financing facility, extending its cash runway into 2028, and made progress on its pipeline assets, including dosing the first patient in a pivotal Phase 3 common warts trial and advancing preparations for VP315's Phase 3 program. Global expansion efforts for YCAMP are also underway with a new distribution agreement in Israel.